长药控股（300391） 投资者索赔案前期已有胜诉判决

Core Viewpoint - The ongoing investor compensation case against Changyao Holdings (300391) is driven by allegations of false statements, with a precedent of investor victories in similar claims [1][2][3] Group 1: Legal Proceedings - Changyao Holdings has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into false financial reporting, leading to a formal case being opened [3] - The law firm Shanghai Jiucheng has filed a compensation case on behalf of investors with the Wuhan Intermediate People's Court, awaiting further court arrangements [1][2] - Investors who purchased Changyao Holdings stock between March 30, 2019, and April 30, 2024, and sold or held the stock after April 30, 2024, are eligible to initiate compensation claims [2][4] Group 2: Financial Issues - Changyao Holdings reported a significant fund occupation amounting to 179,662,019.54 yuan, which represents 92.08% of the company's most recent audited net assets [4] - The company plans to clear the occupied funds through the transfer of debts and credits with related parties [4] - An audit report from Zhongshun Yatai Accounting Firm highlighted major uncertainties regarding the company's ongoing operations, indicating serious financial concerns [3]